中泰国际每日晨讯-20251215

Market Overview - On December 12, the Central Economic Work Conference emphasized the need for internal strengthening to address external challenges and to continue implementing a moderately loose monetary policy[1] - The Hang Seng Index rose by 446 points (1.8%) to close at 25,976 points, with a peak increase of 475 points during the day[1] - The Hang Seng Technology Index increased by 103 points (1.9%) to close at 5,638 points, with total market turnover expanding to HKD 242.7 billion[1] - Southbound capital experienced a net outflow of HKD 5.29 billion[1] Sector Performance - Gold prices increased, with Zijin Mining (2899 HK) rising by 3.6%, Shandong Gold (1787 HK) and Zhaojin Mining (1818 HK) both up by 3.4%[1] - Consumer stocks performed well, with Mengniu Dairy (2319 HK) up 2.7%, Nongfu Spring (9633 HK) up 2.2%, and Haidilao (6862 HK) up 2.9%[1] - Technology stocks also saw gains, with Alibaba (9988 HK) and Tencent (700 HK) rising by 2.3% and 2.4%, respectively[1] U.S. Market Dynamics - Despite interest rate cuts, U.S. tech stocks continued to decline, with the Nasdaq Composite falling by 245 points (0.5%) to close at 48,458 points[2] - The S&P 500 index dropped by 73 points, closing at 6,827 points, while long-term bond yields rose to 4.189%[2] Macroeconomic Indicators - As of the end of November, China's broad money supply (M2) stood at CNY 336.99 trillion, growing by 8% year-on-year, slightly below the market expectation of 8.2%[3] - Narrow money supply (M1) reached CNY 112.89 trillion, with a year-on-year growth of 4.9%, also below the expected 5.7%[3] - The loan balance grew by 6.4% year-on-year, down from the previous 6.5%[3] Industry Insights - In the automotive sector, stocks related to smart driving performed well, with Xiaoma Zhixing (2026 HK) up 4.9% and Horizon Robotics (9660 HK) up 3.8%[4] - The energy/utilities sector saw traditional power equipment stocks rise, with Dongfang Electric (1072 HK) increasing by 16.8% over the week[4] - The pharmaceutical sector remained stable, with WuXi AppTec (2359 HK) and WuXi Biologics (2269 HK) showing solid performance despite potential regulatory challenges[5]